UNASSIGNED: Current methods for diagnosis and staging of prostate @entity420 are not sensitive enough to distinguish between @entity1 with @entity66 and those that should receive radical treatment. Epithelial-mesencyhmal transition (EMT) is a well-characterized process involved in @entity5 invasion and @entity3 . The aim of this study is to analyze the expression of @entity3546 , @entity4245 , and @entity5962 in @entity263 @entity1 with prospective evaluation of their value in predicting @entity66 ( @entity66 ). One-hundred-and-three consecutive @entity263 @entity1 who underwent radical prostatectomy and 35 @entity1 with @entity1067 ( @entity1067 ) were enrolled. Age, initial PSA level, @entity5 size and clinical stage were documented for @entity420 @entity1 and they were enrolled in active surveillance with serum PSA levels. Recurrence was defined as PSA level of >= 0.2  ng/ml on at least 2 occasions over a 2-month period. Immunohistochemical staining intensity was scored as negative, weakly positive, moderately positive, and strongly positive. For @entity4245 and @entity3546 immunoreaction, the @entity5 were considered nuclear positive when more than 5  % of the nuclei of @entity5 cells were positively stained. @entity1 with @entity263 had weaker @entity3546 (p   <   0.0001), @entity4245 (p   =   0.006), and @entity5962 (p   =   0.02) staining when compared to @entity1067 @entity1 and the frequency of nuclear positivity for @entity3546 and @entity4245 were higher in @entity420 group (p   <   0.0001). Increased expression and nuclear positivity of @entity3546 were associated with advanced stage (p   =   0.012 and p   =   0.003) and higher @entity5 volume (p   =   0.013 and p   =   0.002). Additionally, @entity1 with increased @entity4245 expression had higher Gleason scores and @entity5 volume at presentation (p   =   0.008 and p   =   0.004). However, there were no significant @entity66 differences in @entity420 @entity1 who did and did not have @entity3546 , @entity4245 , and @entity5962 expression as assessed with log-rank test. Expressions of @entity3546 , @entity4245 , and @entity5962 were significantly lower in @entity263 @entity1 compared to @entity1067 @entity1 and both @entity3546 and @entity4245 had nuclear staining pattern in @entity1 with @entity420 . However, none of these markers predicted @entity66 in 36-month follow up of our cohort.

Epithelial-Mesenchymal Transition Markers @entity3546 , @entity4245 , and XXXX do not Predict Disease Free @entity263 : a Prospective Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'prostate carcinoma'] @entity66 :: ('MESH:D004194', 'Disease') :: ['indolent disease', 'DFS', 'disease-free survival'] @entity4245 :: ('6615', 'Gene') :: ['Snail'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity1067 :: ('MESH:D011470', 'Disease') :: ['benign prostate hyperplasia', 'BPH'] @entity5962 :: ('999', 'Gene') :: ['E-cadherin'] @entity3546 :: ('1499', 'Gene') :: ['b-catenin'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity5962 :: (999,Gene) :: ['E-Cadherin']
